ERBB2 and ovarian carcinoma: We believe that mPEG × HER2-modified PLD can elevate susceptibility of ovarian cancer cells to PLD and eliminate residual cancer cells, thereby decreasing the frequency of relapse disease to achieve more effective targeted therapy of ovarian cancer.